Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock at a public offering price of $3.90 per share. The offering is expected to close on or around August 15, 2025 subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses are expected to be approximately $15,023,381.10. BioSig intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital and for general corporate purposes.
CALGARY, Alberta, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PHX Energy Services Corp. ("PHX Energy" or the "Corporation") (TSX: PHX) today announced that the Toronto Stock Exchange ("TSX") has accepted PHX Energy's notice of intention to renew its normal course issuer bid for a further one-year term (the "NCIB"). The previous NCIB expires on August 15, 2025. Pursuant to the Corporation's previous NCIB, as at August 5, 2025 the Corporation has purchased in the open market through the facilities of the TSX and through other alternative Canadian trading platforms and cancelled an aggregate of 1,451,111 common shares ("Common Shares") of the Corporation at an average price paid of $9.54 per Common Share.
MONTRÉAL, Aug. 13, 2025 /CNW/ - SYDNEY, August 14, 2025 - Champion Iron Limited (TSX: CIA) (ASX: CIA) (OTCQX: CIAFF) ("Champion" or the "Company") announces...
Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”) which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM) today announced its intention to offer shares of common stock (or pre-funded warrants in lieu thereof) through an underwritten public offering. All of the shares of common stock (or pre-funded warrants in lieu thereof) are being offered by the Company. The completion of the offering remains subject to market conditions, with no assurance regarding its timing, size, or terms. The Company intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital and for general corporate purposes.
VERO BEACH, Fla., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (the “Company”) (NYSE: ORC) announced today that the Board of Directors of the Company declared a monthly cash dividend for the month of August 2025. The dividend of $0.12 per share will be paid September 29, 2025 to holders of record of the Company’s common stock on August 29, 2025, with an ex-dividend date of August 29, 2025. The Company plans on announcing its next common stock dividend on September 8, 2025.
ST. PAUL, Minn., Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV, "Company" or "Solventum") today announced the launch of a secondary offering (the "Offering")...
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit.
HOUSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced it has entered into definitive agreements to acquire two entities (Peak Exploration and Production LLC and Peak BLM Lease LLC, together “Peak”) majority owned by funds of Yorktown Energy Partners LLC.
COTTAGE GROVE, Minn., Aug. 13, 2025 /PRNewswire/ -- TravelNet Solutions (TNS), makers of Track Property Management Software, today announced that finance veteran Priya Arora...
Chart-Topping Latin Icons, Global Art, and a Cultural Feast Take Over Downtown Atlanta This October
ATLANTA, Aug. 13, 2025 /PRNewswire/ -- Atlanta is about to...
World Liberty Financial, with the Trump family at the helm, is trying to get investors to gamble on its self-branded cryptocurrency, WLFI, through the...
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions. In addition, Compass has granted the underwriters a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount.